Q2 2026 report
Spółka technologiczna (fotonika + biologia molekularna) rozwijająca platformę diagnostyczną inPROBE® dla wyrobów medycznych, w II kwartale 2026 zanotowała szereg realnych kamieni milowych regulacyjnych i prawnych, ale wciąż bez istotnych powtarzalnych przychodów komercyjnych.
Sentiment
Cautious
No guidance change
SDS
Q2 2026 report
Revenue
651,385 PLN
— YoY
Net income
-810,685 PLN
— YoY
EBITDA
-362,772 PLN
— YoY
FCF
-1,472,661 PLN
— YoY
Summary
Investment thesis
- Prawomocne zakończenie wieloletniego sporu z NCBR na korzyść Spółki (maj 2026) usuwa ryzyko prawne rzędu ok. 585 tys. zł związane z rozliczeniem projektu Strategmed.
- Ekstremalna dźwignia finansowa: 14,5 mln zł długoterminowego finansowania z Europejskiego Banku Inwestycyjnego wobec 1,3 mln zł kapitału własnego Grupy (dług/kapitał własny ok. 11x).
- Operacyjny cash burn 3,01 mln zł w I półroczu 2026 przy 992,2 tys. zł gotówki na koniec okresu — zależność od kolejnego finansowania (emisji akcji, dotacji, transzy EBI) w perspektywie kwartałów.
- Umowa dystrybucyjna z ACCREA Medical Robotics (sierpień 2026, po dniu bilansowym) i negocjacje z partnerem z USA to pierwsze realne kroki w stronę komercjalizacji, na razie bez potwierdzonej skali przychodów.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
SDS · Q2 2026
| Metric | Q2 2026 | Q2 2025 | Δ YoY | YTD 2026 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|---|---|
| Revenue | 651,385 | — | — | 1,242,241 | — | reported | — | 1.00 |
| EBITDA | -362,772 | — | — | -617,657 | — | derived | — | 0.90 |
| EBIT | -492,041 | — | — | -940,437 | — | reported | — | 1.00 |
| EBT | -758,051 | — | — | -1,648,773 | — | reported | — | 1.00 |
| Net income | -810,685 | — | — | -1,699,078 | — | reported | — | 1.00 |
| D&A | 129,269 | — | — | 322,780 | — | reported | — | 1.00 |
| Interest expense | 243,733 | — | — | 479,521 | — | reported | — | 1.00 |
| Income tax | 51,946 | — | — | 51,946 | — | reported | — | 1.00 |
| EBITDA margin | — | — | — | -49.72% | — | reported | — | 0.40 |
| EBIT margin | — | — | — | -75.71% | — | reported | — | 0.40 |
| Net margin | — | — | — | -136.79% | — | reported | — | 0.40 |
| Cash | 992,192 | — | — | — | — | reported | — | 1.00 |
| Total debt | 14,519,569 | — | — | — | — | reported | — | 0.85 |
| Net debt | 13,527,377 | — | — | — | — | reported | — | 0.80 |
| Equity | 1,309,049 | — | — | — | — | reported | — | 1.00 |
| Total assets | 17,130,707 | — | — | — | — | reported | — | 1.00 |
| Working capital | 1,596,547 | — | — | — | — | reported | — | 0.90 |
| Current assets | 2,288,476 | — | — | — | — | reported | — | 1.00 |
| Current liabilities | 691,929 | — | — | — | — | reported | — | 1.00 |
| Non-current liabilities | 14,519,569 | — | — | — | — | reported | — | 1.00 |
| Inventory | 9,400 | — | — | — | — | reported | — | 1.00 |
| Trade receivables | 490,651 | — | — | — | — | reported | — | 1.00 |
| Goodwill | 1,908 | — | — | — | — | reported | — | 1.00 |
| CFO | -1,472,661 | — | — | -3,013,491 | — | reported | — | 1.00 |
| CapEx | 0 | — | — | 0 | — | reported | — | 1.00 |
| FCF | -1,472,661 | — | — | -3,013,491 | — | derived | — | 1.00 |
| Current ratio | 3.31x | — | — | — | — | reported | — | 0.90 |
| Quick ratio | 3.29x | — | — | — | — | reported | — | 0.90 |
| Cash ratio | 1.43x | — | — | — | — | reported | — | 0.90 |
| Interest coverage | — | — | — | -1.96x | — | reported | — | 0.60 |
| Debt / equity | 11.09x | — | — | — | — | reported | — | 0.80 |
| Debt / assets | 0.85x | — | — | — | — | reported | — | 0.85 |
| Net debt / equity | 10.34x | — | — | — | — | reported | — | 0.80 |
| Revenue growth (YoY) | — | — | — | -32.18% | — | reported | — | 0.50 |
| EBITDA growth (YoY) | — | — | — | 43.33% | — | reported | — | 0.60 |
| EBIT growth (YoY) | — | — | — | 36.15% | — | reported | — | 0.70 |
| Net income growth (YoY) | — | — | — | 9.24% | — | reported | — | 0.70 |
Q2 2026 · Δ YoY
Revenue
651,385
—
651,385
—
- Q2 2025
- —
- YTD 2026
- 1,242,241
- Δ YoY
- —
EBITDA
-362,772
—
-362,772
—
- Q2 2025
- —
- YTD 2026
- -617,657
- Δ YoY
- —
EBIT
-492,041
—
-492,041
—
- Q2 2025
- —
- YTD 2026
- -940,437
- Δ YoY
- —
EBT
-758,051
—
-758,051
—
- Q2 2025
- —
- YTD 2026
- -1,648,773
- Δ YoY
- —
Net income
-810,685
—
-810,685
—
- Q2 2025
- —
- YTD 2026
- -1,699,078
- Δ YoY
- —
D&A
129,269
—
129,269
—
- Q2 2025
- —
- YTD 2026
- 322,780
- Δ YoY
- —
Interest expense
243,733
—
243,733
—
- Q2 2025
- —
- YTD 2026
- 479,521
- Δ YoY
- —
Income tax
51,946
—
51,946
—
- Q2 2025
- —
- YTD 2026
- 51,946
- Δ YoY
- —
EBITDA margin
—
—
—
—
- Q2 2025
- —
- YTD 2026
- -49.72%
- Δ YoY
- —
EBIT margin
—
—
—
—
- Q2 2025
- —
- YTD 2026
- -75.71%
- Δ YoY
- —
Net margin
—
—
—
—
- Q2 2025
- —
- YTD 2026
- -136.79%
- Δ YoY
- —
Cash
992,192
—
992,192
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total debt
14,519,569
—
14,519,569
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt
13,527,377
—
13,527,377
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Equity
1,309,049
—
1,309,049
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total assets
17,130,707
—
17,130,707
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Working capital
1,596,547
—
1,596,547
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current assets
2,288,476
—
2,288,476
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current liabilities
691,929
—
691,929
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Non-current liabilities
14,519,569
—
14,519,569
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Inventory
9,400
—
9,400
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade receivables
490,651
—
490,651
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Goodwill
1,908
—
1,908
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
CFO
-1,472,661
—
-1,472,661
—
- Q2 2025
- —
- YTD 2026
- -3,013,491
- Δ YoY
- —
CapEx
0
—
0
—
- Q2 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
FCF
-1,472,661
—
-1,472,661
—
- Q2 2025
- —
- YTD 2026
- -3,013,491
- Δ YoY
- —
Current ratio
3.31x
—
3.31x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Quick ratio
3.29x
—
3.29x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Cash ratio
1.43x
—
1.43x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Interest coverage
—
—
—
—
- Q2 2025
- —
- YTD 2026
- -1.96x
- Δ YoY
- —
Debt / equity
11.09x
—
11.09x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / assets
0.85x
—
0.85x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt / equity
10.34x
—
10.34x
—
- Q2 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Revenue growth (YoY)
—
—
—
—
- Q2 2025
- —
- YTD 2026
- -32.18%
- Δ YoY
- —
EBITDA growth (YoY)
—
—
—
—
- Q2 2025
- —
- YTD 2026
- 43.33%
- Δ YoY
- —
EBIT growth (YoY)
—
—
—
—
- Q2 2025
- —
- YTD 2026
- 36.15%
- Δ YoY
- —
Net income growth (YoY)
—
—
—
—
- Q2 2025
- —
- YTD 2026
- 9.24%
- Δ YoY
- —